Repurposing Public 24Q2

This data release contains two most recent PRISM Repurposing screens: Repurposing-1M and Repurposing-300. All Repurposing-1M [REP1M] and Repurposing-300 [REP300] compounds (1514 = 1280 REP1M + 234 REP300) were screened in the PRISM assay at a dose of 2.5 μM with a 5-day treatment against 906 cancer cell lines (859 of them passed quality checks -QC- for all tested compound with two high quality replicates). Two PRISM cell line collections were used in the assay: PR500A, which includes only adherent cell lines, and PR500B, which has adherent and suspension cell lines. Together, these PRISM cell line collections form the PR1000 cell line collection. All compounds were run in triplicate, and each plate contained positive (Bortezomib, 20μM) and negative (DMSO) controls. The screen can be considered an extension of the PRISM Repurposing Primary Screen, with PR500A mainly covering the existing cell line panel, while PR500B extends the cell line collection with new subtypes and lineages. For the assay details, please refer to Corsello et al., 2020 (doi.org/10.1038/s43018-019-0018-6) and https://www.theprismlab.org.

本数据集发布包含最新的两项PRISM药物重定位筛选项目：Repurposing-1M（缩写REP1M）与Repurposing-300（缩写REP300）。所有Repurposing-1M（REP1M）与Repurposing-300（REP300）所涵盖的化合物共计1514种（其中REP1M组1280种，REP300组234种），均在PRISM检测体系中以2.5 μM的浓度、5天的处理时长，对906株癌细胞系开展筛选；其中859株细胞系在所有受试化合物的检测中均通过了质量控制（quality check，QC），且每份检测设置了两份高质量生物学重复。本次筛选使用了两套PRISM细胞系库：仅包含贴壁细胞系的PR500A，以及同时涵盖贴壁与悬浮细胞系的PR500B。两套细胞系库共同构成了PR1000总细胞系库。所有化合物均设置三次生物学重复，每块检测微孔板均包含阳性对照（硼替佐米（Bortezomib），20μM）与阴性对照（二甲基亚砜（DMSO））。本次筛选可视为PRISM药物重定位初级筛选的延伸：PR500A主要覆盖原有细胞系组，而PR500B则通过新增细胞亚型与谱系进一步拓展了细胞系库。有关本次检测的详细方法，请参考Corsello等人2020年发表的研究（doi.org/10.1038/s43018-019-0018-6）以及PRISM实验室官方网站https://www.theprismlab.org。